Hepatitis C virus is a leading cause of chronic hepatitis and liver cancer. Little information exists on the interplay between innate defense mechanisms and viral antagonists that promote viral egress. Herein, the effects of Tetherin/BST-2 on HCV release were investigated. In Huh-7.5 hepatocytes, low expression levels of BST-2 were detected. Treatment of Huh-7.5 cells with IFNa, elevated BST-2 expression levels. However, HCV could not alter the expression of IFNa-induced BST-2, nor of stably over-expressed BST-2. Significantly, over expressed BST-2 moderately blocked HCV production and release from Huh-7.5 cells.
Introduction
Hepatitis C virus (HCV) is a leading cause of chronic hepatitis, cirrhosis, and liver cancer worldwide. It is a major public health problem, persistently infecting nearly 200 million people worldwide. A vaccine against HCV is yet to be developed and current anti-viral therapy is based on pegylated interferon a (IFNa) in combination with ribavirin, which results in only limited sustained virological response and severe side effects (Moradpour et al., 2007; Wasley and Alter, 2000; Williams, 2006) .
HCV is a 9.6 kb positive single-stranded RNA that replicates primarily in hepatocytes (Choo et al., 1989; Kolykhalov et al., 1997; Poynard et al., 2003) . The viral genome is translated to a single polyprotein of 3000 residues that is processed by host and viral proteases into structural and non-structural (NS) proteins (Appel et al., 2006; Bartenschlager et al., 2004; Murray et al., 2008) . Efficient systems to propagate HCV in culture have been recently developed and helped to characterize the different steps of HCV life cycle and to identify host proteins that support these steps . Several host receptors and cofactors involved in viral entry and receptor-mediated clathrin endocytosis were identified (Bartosch et al., 2003a; Bartosch et al., 2003b; Blanchard et al., 2006; Codran et al., 2006; Evans et al., 2007; Ploss and Rice, 2009; Randall et al., 2007) . HCV replication occurs on endoplasmic reticulum (ER) associated membranous web structures (Egger et al., 2002; Gosert et al., 2003; Moradpour et al., 2003) , and viral RNA in complex with viral and cellular proteins are then transferred to lipid droplets (LD), where viral assembly takes place Counihan et al., 2011; Miyanari et al., 2007) . In this step, NS proteins, including p7, NS2, NS3, and NS5A are important. Late events of HCV release are less clear Ng et al., 2007; Randall et al., 2007; Tai et al., 2009 ). Flaviviruses egress is thought to occur via secretory pathways and HCV may utilize similar pathways to release from infected cells (Lindenbach and Rice, 2003; Mackenzie and Westaway, 2011) . However, HCV is distinct as particles become infectious only after acquiring the envelope and are secreted from cells in association with distinct lipid and apolipoprotein via the secretory pathwayfrom trans-Golgi Network (TGN) (Chang et al., 2007; Jiang and Luo, 2009; Merz et al., 2011) . Recent siRNA screens had identified numerous host proteins of the secretory pathway that co-traffic with HCV core and are required for HCV release. Components of ER to Golgi trafficking (SAR1A), Golgi structure and function (CYTH3), cargo sorting and vesicle budding from TGN (PRKD1, AP1M1, PI4KB, CLINT1), regulators of TGN to plasma membrane trafficking (RAB11A, RAB3D, PACSIN3) and the v-snare, VAMP1 were all identified Coller et al., 2009 Coller et al., , 2012 The ability of HCV to evade the host innate immune response is fundamental for completion of its replication cycle and establishing persistence. Viral RNA triggers innate antiviral response, which leads to the synthesis of IFNa and IFNb. The virus activates the RNA helicase retinoic acid inducible gene protein I [RIG-I] , which recognizes the foreign viral RNA. However, in contrast to other RIG-I activating viruses, HCV is a poor IFN and proinflammatory cytokine inducer. It mainly establishes chronic infection due to the inefficiency of the host innate response to antagonize viral evasion strategies. These include the activity of NS3/4A protease that targets key components of the innate response, the viral core protein that targets components of the JAK/STAT pathways and E2/NS5A that bind to PKR and inhibit (in some genotypes) its activation. NS5A also targets the antiviral activity of oligoadenylate synthetase (2-5 OAS) (Taguchi et al., 2004) . Nevertheless, despite early disruption of the host innate response, IFN type I stimulated gene expression (ISG) is elevated during the first 12 h of HCV infection, after which a rapid decline at the protein level, rather than at the RNA level occurs. In addition, microarray analysis of liver samples from HCV-infected chimpanzees or chronically infected humans also show increased ISGs expression, among them PKR; ISG56; ISG20; ADAR1 and viperin are elevated in Bigger et al. (2004) , Foy et al. (2005) , Gale and Foy (2005) , Pezacki et al. (2009) , Saito and Gale (2008) , Sarasin-Filipowicz et al. (2008) , Sklan et al. (2009) , Su et al. (2002) and Sumpter et al. (2005) .
Human BST-2/CD317/Tetherin is an IFN-type I induced, type II glycosylated protein that is mainly localized to the surface plasma membrane. It also associates with lipid rafts at the cell surface and with internal membranes, presumably in the TGN (Andrew et al., 2011; Dube et al., 2009; Hauser et al., 2010; Masuyama et al., 2009 ). BST-2 was identified as a host restriction factor that disrupts the release of vpu defective HIV particles. Nascent particles assemble at the cell surface, but remain tethered to the infected cell by BST-2 before being endocytosed and accumulated into late endosomes. BST-2 disrupts the release of a broad spectrum of viruses that either bud from cholesterol-enriched domains of the plasma membrane (HIV and Ebola), or from the endoplasmic reticulum and trans-Golgi network, followed by transport to the cell surface in secretory vesicles (KSHV and Herpesvirus) (Dietrich et al., 2011; Goffinet et al., 2009 Goffinet et al., , 2010 Groom et al., 2010; Gupta et al., 2009; Lopez et al., 2010; Neil et al., 2007 Neil et al., , 2008 Perez-Caballero et al., 2009; Radoshitzky et al., 2010; Ruiz et al., 2010; Watanabe et al., 2011) . To replicate in this hostile environment, viruses have developed antagonists that counteract the restriction of BST-2 and promote viral release. In HIV-1, the accessory protein vpu interacts with BST-2 and accelerates viral release by downregulating surface expression of BST-2, targeting it to degradation. Similarly, SIV Nef, KSHV K5 and HIV-2 GP also target BST-2 activity (Douglas et al., 2010; Le Tortorec and Neil, 2009; Miyagi et al., 2009; Pardieu et al., 2010; Sauter et al., 2009) .
In this study we investigated the role of BST-2 in modulating HCV replication at steps of viral production and release. Indeed, microarray analyses that monitored the expression of BST-2 in HCV infected cells are controversial, but some do demonstrate that BST-2 expression is modulated in vivo upon HCV infection (Bigger et al., 2004; Pezacki et al., 2009; Sarasin-Filipowicz et al., 2008; Su et al., 2002) . Moreover, BST-2 expression levels are moderately high in liver tissue (Erikson et al., 2011) . HCV does not bud via the membrane of infected cells, but is thought to replicate on detergentinsoluble sub-cellular domains or lipid rafts membrane web structures, where BST-2 is expressed. Upon subjecting HCV infected cells to membrane flotation analysis, both viral NS proteins and RNA were localized distinctively to these specific sub-domains (Gao et al., 2004; Amemiya et al., 2008; Miyanari et al., 2007) .
Herein, only low basal expression levels of BST-2 were detected in Huh-7.5 cells. HCV infection could not alter the low basal expression levels of BST-2. Treatment of Huh-7.5 cells with IFNa, induced expression levels of BST-2. However, IFNamediated expression of BST-2 also was not modulated following HCV infection. Similarly, expression levels of IFNa-induced BST-2 were not changed when cells were first infected with HCV and then treated with IFNa. As HCV cannot replicate in IFNa treated cells, where BST-2 is induced, Huh-7.5-BST-2 stable cells were generated by lentiviral transduction and sorting cells for high BST-2 expression. In Huh-7.5-BST-2 cells, BST-2 expression levels were also not down regulated upon HCV infection. Significantly, stably expressed BST-2 moderately blocked the release of HCV from producing cells, as well as restricted HCV release and also decreased cell associated viral particles from infected Huh-7.5 cells. Stably expressed BST-2 also inhibited the release of HIV-delta Vpu from Huh-7.5-BST-2 cells, validating its function as an inhibitor of HIV-delta vpu release from Huh-7.5 cells. Over expression of vpu, rescued the release of HIV-delta Vpu virus from Huh-7.5-BST-2 cells. Over expression of HIV vpu in Huh-7.5-BST-2, only partially rescued the block in HCV release and production, which was mediated by BST-2. We conclude that in vitro, BST-2 moderately modulates the replication of HCV at the steps of viral production and release, while the virus lacks the mechanisms to counteract this restriction. Furthermore, our study establishes a possible role for human BST-2 in restricting late steps of HCV particle release and highlights the continuous battle between viral and host antiviral innate defense mechanisms.
Results
BST-2 expression levels are low in HCV permissive Huh-7.5 cells and are induced by IFNa Huh-7.5 hepatocytes were initially analyzed for their basal expression levels of BST-2. Cells were analyzed by FACS for BST-2 expression using an anti BST-2 polyclonal antibody, followed by staining with a secondary anti-rabbit-Rhodamine Red-X conjugated secondary antibody. Results show that Huh-7.5 cells expressed low levels of BST-2 ( Fig. 1A and B) . Only 10% of Huh-7.5 cells positively stained for BST-2, exhibiting relatively low MFI values of 564. As BST-2 expression is induced by IFNa, Huh-7.5 cells were also treated with increasing concentrations of IFNa. 24 h post-treatment, cells were analyzed by FACS for BST-2 expression. Treatment of cells with IFNa led to elevated expression levels of BST-2. Induction of BST-2 expression by IFNa was detected in both the percentage of cells that were stained positively for BST-2 and in the MFI values obtained in the FACS analysis and compared to those obtained for Huh-7.5 nontreated cells (Fig. 1A and B) . Fig. 1B left panel represents FACS analysis for BST-2 expression in Huh-7.5 cells and the right panel, represents BST-2 expression in Huh-7.5 cells that were treated with 500 U/ml IFNa). As not all cells were equally induced by IFNa, these results indicated that BST-2 expression levels were induced by IFNa at the level of a given cell. Expression of BST-2 following IFNa treatment was also analyzed by western blot. BST-2 expression levels in Huh-7.5 were non-detectable, while treatment of cells with 500 U/ml IFNa, resulted in elevated BST-2 expression levels ( Fig. 1C; lane 2) . We conclude that in HCV permissive Huh-7.5 cells, BST-2 expression levels are low and are induced upon treatment with IFNa.
HCV cannot modulate the expression levels of basal or IFNa induced BST-2
We then asked if HCV could modulate basal or IFNa-induced expression levels of BST-2. Huh-7.5 cells were infected with a monocistronic FL-J6/JFH-5.C19Rluc2AUbi HCV (RLuc-HCV), which expressed a luciferase reporter gene . 48 h or 72 h post-infection cells were analyzed for endogenous BST-2 expression by FACS. Low BST-2 expression levels were detected in Huh-7.5 cells that were not treated with IFNa. Only 10% of the cells were stained positively for BST-2 and MFI levels were also basal, confirming the results obtained in Fig. 1 ( Fig. 2A ; white bar). Moreover, infection of Huh-7.5 cells with RLuc-HCV did not alter the endogenous expression levels of BST-2 that remained at their basal levels 48 h and 72 h post-infection ( Fig. 2A ; black bars; lanes 3 and 4). To verify HCV infection in this experimental setting, infected cell were lysed and analyzed for viral replication by monitoring their luciferase activity (Fig. 2B) . RLuc-HCV efficiently replicated in Huh-7.5 cells. We conclude that HCV cannot modulate basal BST-2 expression in HCV infected Huh 7.5 cells.
To test if HCV can modulate expression levels of IFNa-induced BST-2, Huh-7.5 cells were first treated with IFNa (1000 U/ml) to induce BST-2 expression and 24 h later IFNa was washed away.
Cells were then either infected with RLuc-HCV or remained noninfected. At the indicated time points post-IFNa removal, cells were harvested and BST-2 expression levels were analyzed by western blot (Fig. 3A) . In HCV non-infected Huh-7.5 cells that were not treated with IFNa, BST-2 expression was not detectable ( Fig. 3A; lane 1) . Treatment of cells with IFNa, induced expression of BST-2, as detected 24 h post-removal of IFNa ( Fig. 3A; lane 2). BST-2 displayed typical migration patterns on SDS-PAGE, reflecting differential N-glycosylation and dimer formation. At later points (48 h and 72 h) post-IFNa removal, BST-2 expression levels in non-infected Huh-7.5 cells decreased. Expression of dimeric forms diminished and BST-2 levels reached basal non-detectable levels at 72 h post-IFNa removal ( Fig. 3A ; lanes 3 and 4). Importantly, similar kinetics of reduction of BST-2 expression post-IFNa removal was observed in cells that were treated with IFNa to induce BST-2 expression and then were infected with RLuc-HCV ( HCV could not modulate BST-2 expression levels that were induced by IFNa. HCV replication was also monitored in Huh-7.5 cells that were treated with 1000 U/ml IFNa ( Fig. 3B ; white bars) and compared to cells that were not treated with IFNa ( Fig. 3B ; black bars). As expected, HCV replication was substantially decreased in cells that were treated with IFNa, emphesizing that HCV could not modulate the expression of BST-2 that was induced by IFNa. We conclude that the decrease in BST-2 expression levels following removal of IFNa were not due to HCV ability to down-regulate the expression of BST-2 (Fig. 3B) .
BST-2 expression levels in Huh-7.5 cells were also monitored by western blot upon initial infection of Huh-7.5 with RLuc-HCV. 48 h post-infection, BST-2 expression was induced by treatment of infected cells with IFNa (1000 U/ml). 48 h post-IFNa treatment, BST-2 expression in HCV infected cells was analyzed by western blot (Fig. 3C ). This experimental setting fitted better to clinical protocols which includes treatment with IFNa following HCV infection. In HCV infected Huh-7.5 cells, BST-2 expression levels were non-detectable and comparable to BST-2 basal levels observed in non-infected cells ( Fig. 3C ; compare lanes 1 and 2). Treatment of Huh-7.5 cells with IFNa, induced BST-2 expression ( Fig. 3C lane 3) . Moreover, in cells that were first infected with HCV and 48 h later were treated with IFNa, BST-2 expression levels remained high and comparable to BST-2 levels that were detected in non-infected cells that were treated with IFNa (compare lanes 3 and 4). These results confirmed that initial HCV infection also could not modulate IFNa-induced BST-2 expression.
HCV cannot modulate the expression levels of stably expressed BST-2
Since in Huh-7.5 cells BST-2 expression was only induced following treatment of cells with IFNa, where HCV could not replicate, Huh-7.5 cells that stably expressed BST-2 were generated using lentiviruses that promoted BST-2 expression under the CMV promoter. The lentivector also coded for a puromycin resistant gene that was expressed via an IRES sequence. Transduced cells were selected on puromycin and were further sorted based on their BST-2 expression to obtain cells that highly expressed BST-2 (referred to as Huh-7.5-BST-2). Expression of BST-2 in Huh-7.5-BST-2 stable cells was verified by FACS analysis. 98.8% of cells were stained positively for BST-2 and MFI values of the FACS analysis were 1766, as compared to MFI of 564 Huh-7.5 expressing basal BST-2 expression (Fig. 4A; compare with Fig. 1B) . Western blot analysis of Huh-7.5-BST-2 confirmed high levels of BST-2 expression as compared to basal levels of BST-2 that were not detectable in Huh-7.5 cells ( Fig. 4B; compare lanes 1 and 2) . Furthermore, immunofluorescence analysis (IFA) of Huh-7.5-BST-2 stable cells also verified high BST-2 expression in all cells, as compared with Huh-7.5 cells, where BST-2 expression was almost not detected (compare Fig. 4C ; images a and b). BST-2 expression in Huh-7.5-BST-2 stable cells was also detected intracellularly, following permeabilization of Huh-7.5-BST-2 cells. Herein, BST-2 expression was also visualized in the cytoplasm ( Fig. 4C ; image c). Bright-field images corresponded to matched of the IFA images ( Fig. 4 ; Panels d-f).
To test if HCV could modulate the expression of stably-expressed BST-2, Huh-7.5-BST-2 cells were infected with RLuc-HCV and at the indicated time points (48 h and 72 h post-infection), cells were harvested and analyzed by FACS for BST-2 expression (Fig. 5A ). BST-2 expression levels remained similar 48 h and 72 h postinfection and were comparable with BST-2 expression levels in non-infected Huh-7.5-BST-2 cells ( Fig. 5A ; compare gray bar with black bars at lanes 3 and 4). MFI values of basal BST-2 expression in Huh-7.5 were relatively low, confirming the results that were obtained in Fig. 1 (white bar) . In Huh-7.5-BST-2, MFI values were much higher. Overall, stable BST-2 expression levels were not modulated in Huh7.5-BST-2 cells that were infected with HCV.
Western blot analysis also monitored the expression of BST-2 in Huh-7.5-BST-2 cells that either remained non-infected ( Fig. 5B ; lanes 3-5), or were infected with RLuc-HCV ( Fig. 5B; lanes 6-8) . Similar expression levels of BST-2 were detected at the indicated time points in cells that were infected with HCV or remained noninfected. (Fig. 5B ; compare lanes 3-5 with lanes 6-8). Western blot analysis for b-actin confirmed equal amounts of protein that were loaded on the gel ( Fig. 5B; lower panel) . Importantly, at the same time points post-HCV infection, Huh-7.5 and Huh-7.5-BST-2 infected cells were monitored for their HCV replication (Fig. 5C ). HCV efficiently replicated in Huh-7.5 and in Huh-7.5-BST-2 stable cells, implying that the virus lacks the mechanisms to modulate BST-2 expression. Significantly, replication efficiencies of RLuc HCV were approximately 2-fold lower in Huh-7.5-BST-2 cells (white bars) as compared to those detected in Huh-7.5 cells (black bars; Fig. 5C ). HCV infected Huh-7.5-BST-2 stable cells were also analyzed for BST-2 and HCV-NS5A expression by FACS. As shown in a representative dot-blot, 85% of cells were both infected with HCV and expressed BST-2. IFA analysis was also performed on Huh-7.5-BST-2 stable cells. Cells were stained for both BST-2 and for HCV-NS5A. As shown, in HCV infected Huh-7.5-BST-2, BST-2 only moderately co-localized with HCV-NS5A ( Fig. 5E ; images a and b).
BST-2 blocks viral release from HCV producing cells
Above results demonstrated that HCV could not modulate BST-2 expression levels that were either induced by IFNa or stably over expressed in Huh-7.5 cells. However, it remained to be verified if over expressed BST-2 affects the production and release of HCV (Fig. 6) . Huh-7.5 that did not express BST-2 (closed circles) or Huh-7.5-BST-2 stable cells (open circles) were electroporated with RLuc-HCV RNA. At the indicated time points post-electroporation, cells were harvested and viral supernatants were collected, clarified and used for infectivity release assays of new Huh-7.5 cells. 72 h post-infection, Huh-7.5 cells were harvested and their viral-mediated luciferase activity was measured (Fig. 6A) . Moderately lower yields of HCV particles were released from Huh-7.5 producing cells that stably expressed BST-2 ( Fig. 6A ; open circles), when compared to viral particle release from HCV producing cells that did not express BST-2 ( Fig. 6A ; closed circles). At early time points post-electroporation, viral release from Huh-7.5-BST-2 stable cells exhibited a low rates of release compared to HCV released from Huh-7.5 control cells that did not express BST-2 (5 fold relative difference at 2 days post-electroporation). As time point post-electroporation advanced, relative differences in HCV release between the two cells types were stabilized around 2-fold in favor of the cells that did not express BST-2 (Fig. 6A) . Huh-7.5-BST-2 stable cells that were electroporated with HCV RNA were also analyzed by FACS for BST-2 and for viral NS5A expression (Fig. 6B) . 89% of cells expressed both BST-2 and HCV NS5A. We conclude that when over expressed, BST-2 moderately restricts HCV release from Huh7.5 producing cells.
BST-2 restricts HCV particle production and release from Huh-7.5 infected cells
To test if BST-2 also restricts HCV release following infection, Huh-7.5-BST-2 cells (open circles) or Huh-7.5 cells that did not express BST-2 (closed circles) were infected with concentrated RLuc-HCV. Infectivity release assays were performed by collecting supernatants from infected cells at the indicated time points post-infection and reinfecting new Huh-7.5 cells (Fig. 7A ). Viral infectivity in Huh-7.5 was monitored 72 h post-infection by measuring luciferase-renilla activity. As these were release assays from HCV infected cells, the second round of infection of Huh-7.5 cells resulted in lower viral luciferase counts. These were approximately 2 log of magnitude lower in both Huh-7.5-BST-2 and Huh-7.5 cells, compared to cells that were directly electroporated with viral RNA and monitored for their luciferase counts (compare to Fig. 6) . Nevertheless, the overall release of HCV particles from infected Huh-7.5-BST-2 cells was lower when compared to virus that was released from Huh-7.5 infected cells that did not express BST-2 (Fig. 7A) . At 28 h post-infection, a 6-fold difference was observed in viral release from Huh-7.5 cells that did not express BST-2, compared to release from Huh-7.5-BST-2 stable cells. At later time points post-infection, differences in HCV release from infected cells were also observed and were 3-3.8-fold at respectively 72 h and 50 h post-infection in favor for Huh-7.5 that did not express BST-2 (Fig. 7A) . In addition, effects of BST-2 on viral production associated within cells were also compared between Huh-7.5-BST-2 and Huh-7.5 cells. (Fig. 7B) . Huh BST-2 expression: Huh-7.5 cells (image a) and Huh-7.5-BST-2 stable cells (image b) were seeded on cover slips and the next day were stained with for BST-2 expression with an anti-BST-2 polyclonal antibody followed by staining with a secondary anti-rabbit Rhodamine antibody. For intracellular staining, cells were also permeabilized before subjected to BST-2 staining (image c). Staining cells with DAPI verified nuclear imaging. Bright field images that match to the same IFA images of Huh-7.5 (image d), Huh-7.5-BST-2 cells (image e) and permeabilized Huh-7.5-BST-2 (image f) are also presented.
yields associated within cells. As early as 30 h post-infection, a 2.7-fold lower viral yields were detected within Huh-7.5-BST-2 stable infected cells, compared with viral yields in Huh-7.5 infected cells. At later time points of 50 h and 72 h post-viral infection, relative differences in cell associated viral production between the two cell types were stabilized at 2-fold in favor of Huh-7.5 cells that did not express BST-2 (Fig. 7B) . Effects of BST-2 on HCV viral production and release were also analyzed by real time PCR analysis, monitoring HCV Huh-7.5 cells (black bars) were infected with RLuc-HCV and at the indicated time post-infection were lysed and subjected to renilla-luciferase measurements. RLU were normalized to ensure equal protein levels that were subjected to the renilla-luciferase assay. Results are representative of the mean values of triplicate wells; error bars show the standard deviation of the means. (D) FACS analysis of efficient HCV replication in Huh-BST-2 stable cells: Huh-7.5-BST-2 cells were infected with RLuc-HCV and 72 h post-infection cells were analyzed by FACS for both BST-2 and HCV NS5A expression. Cells were initially incubated with the primary polyclonal BST-2 and mouse NS5A antibodies, followed by staining with anti-rabbit-Rhodamine Red-X and anti-mouse FITC conjugated antibodies. (E) Immunofluorescence analysis of HCV infected Huh-7.5-BST-2 cells: Huh-7.5-BST-2 cells were seeded on cover slips and were further infected with RLuc-HCV. 48 h post-infection cells were permeabilized and stained for both BST-2 and HCV-NS5A using the appropriate antibodies (image b). Image a corresponds to a matched bright-field image.
RNA levels following infection of Huh-7.5 or Huh-7.5-BST-2. In Huh-7.5-BST-2 cells that, both intracellular and secreted viral RNA levels were relatively lower compared to RNA levels produced or secreted from Huh-7.5 cells ( Fig. 1; supplementary results) . We conclude that BST-2 moderately restricts HCV production following infection.
BST-2 inhibits HIV-delta Vpu release from Huh-7.5 cells
As BST-2 restriction on HCV release was marginal, its functional activity in restricting HIV release from Huh-7.5-BST-2 stable cells was verified. Wild type and delta-Vpu HIV NL4.3 proviruses were produced in Huh-7.5 cells or in Huh-7.5-BST-2 stable cells and 48 h post-transfection supernatants containing virus were used for infectivity assays of reporter TZM-bl cells, as a measurement for particle release (Fig. 8) . Effects of HIV vpu were also monitored by expression of vpu in Huh 7.5 and Huh-7.5-BST-2 cells (1 mg). As shown, wild-type HIV was efficiently released from both Huh-7.5 (black bars) and Huh-7.5-BST-2 (white bars). The release of HIV-delta Vpu particles from Huh-7.5 cells, where BST-2 expression levels were moderately low, was also efficient and at similar levels as the wild type virus. However, the release of HIV-delta Vpu virus from Huh-7.5-BST-2 was substantially inhibited. Over expression of HIV Vpu had no effects on the release of wild-type HIV from both Huh-7.5 and Huh-7.5-BST-2 cells. Importantly, HIV Vpu rescued the release of the delta-Vpu HIV from Huh-7.5-BST-2 stable cells, confirming its ability to antagonize BST-2 activity in Huh-7.5 cells. Wild-type or delta-Vpu proviruses producing cells were also analyzed by western blot analysis for expression of CA-p24 (Serotec), to verify equal levels of cell associated HIV particles that were produced ( Fig. 8 ; lower panel). Vpu expression was also validated by western blot analysis using anti Vpu polyclonal antibody. Western blot analysis for b-actin confirmed equal protein levels that were loaded on the gel. We conclude that in Huh-7.5 cell, stably expressed BST-2 is functional and efficiently restricts HIV-delta Vpu release. Moreover, the Vpu antagonizes the inhibitory effects of BST-2 and rescues HIV-delta Vpu release from Huh-7.5-BST-2 cells.
HIV Vpu partially overcomes BST-2 mediated restriction of HCV
HIV-1 Vpu is known to antagonize the restriction function of BST-2 and promotes HIV particle release presumably via down regulation of surface expression of BST-2. The effects of over expressed Vpu on BST-2 expression in Huh-7.5-BST-2 cells and on the restriction of HCV release were also tested (Fig. 9) . Huh-7.5-BST-2 stable cells were transfected with increasing concentrations of HIV-1 Vpu (5-10 mg) and 48 h post-transfection cells were subjected to FACS analysis to monitor both Vpu (white bars) and BST-2 expression levels (black bars). Over expression of Vpu in Huh-7.5-BST-2 cells led to a relatively minor down regulation of BST-2 surface expression. Depending on the Vpu concentration that was transfected into Huh-7.5-BST-2 cells, a low 1.8-2.7-fold decrease in BST-2 surface expression was observed in cells that over-expressed Vpu, compared to BST-2 expression levels in Huh-7.5-;BST-2 cells that did not express Vpu ( Fig. 9A; compare lanes 1 to lanes 2 and 3) . HCV production was also measured in Huh-7.5-BST-2 cells that over expressed HIV Vpu (Fig. 9B) . Huh-7.5-BST cells were co-electroporated with RLuc-HCV RNA and HIV Vpu expression plasmid (10 mg). Viral production was measured 48 h post-electroporation by harvesting cells and measuring their luciferase-renilla activity (Fig. 9B) . A relatively low (2-fold) decrease of HCV production was observed in Huh-7.5-BST-2, compared to Huh-7.5 infected cells (Fig. 9B , compare gray bar to black bar). Over expression of Vpu, led to a 1.3-fold small increase in HCV production associated with Huh-7.5-BST-2, but not to the same levels as detected in cells that did not express BST-2 (Fig. 9B , compare gray bar at lane 1 to white bar at lane 3). We conclude that over-expressed Vpu negligibley rescues HCV production in Huh-7.5-BST-2 cells. Infectivity assays were also performed, monitoring viral release from Huh-7.5-BST-2 stable cells that co-expressed HIV-1 Vpu. Huh-7.5-BST-2 stable cells were electroporated with HCV RNA and Vpu expression vector. Supernatant was collected 2 day post-electroporation and was used to infect Huh-7.5 cells (Fig. 9C) . A 1.85-fold decrease in release of HCV form Huh-7.5-BST-2 cells was observed (black bar; lane 2), compared to released particles from infected Huh-7.5 cells that did not express BST-2 (gray bar: lane 1). HCV particle release was slightly rescued (1.4-fold) upon over expression of Vpu ( Fig. 9C ; white bar). Lower panel presented levels of Vpu expression as measured by western blot using anti Vpu antibody. Overall, we conclude that Vpu slightly antagonizes the function of BST-2 on viral production and release by moderately modulating the surface expression of BST-2. To verify that the observed moderate rescue effects of HIV vpu on HCV replication and release are statistically significant, we performed a statistical analysis and determined the p values of the above experiments (Fig. 9) . Indeed, the p value for all of the experiments were below 0.05, implying that in Huh-7.5 cells, vpu moderately counteracts the inhibition effects of BST-2 on HCV replication and release.
Discussion
The establishment of in vitro tissue culture systems for production of infectious HCV greatly enhanced the understanding of the complete viral life cycle and the interactions with its host (Murray and Rice, 2011) . While much progress has been made at characterizing early steps of viral entry and replication, insights onto late steps of HCV assembly and release are less understood. Moreover, host factors that regulate viral release are poorly defined (Jones and McLauchlan, 2010) .
Persistence of HCV is established by evading the innate immune response and attenuating the production of IFN Stimulated Genes (ISGs). Despite that, the expression of numerous ISGs is elevated upon HCV infection. However, little is known about their antiviral activity (Haller et al., 2006; Horner and Gale, 2009; Sen and Sarkar, 2007; Sklan et al., 2009) . In a search for novel ISGs that act against important RNA viruses like HCV, Schoggins et al. analyzed the antiviral activity of a wide range of ISGs and demonstrated that different viruses are targeted by different sets of ISGs. Each virus is susceptible to multiple antiviral genes, which together encompass a range of inhibitory functions. RIG-I, MDA-5, IRF1 and IRF7 ISGs possess anti-HCV activity and stimulate the expression of other ISGs that limit HCV replication (Schoggins et al., 2011 ). Yet, while more than 380 ISGs were screened, the described platform used a lentiviral vector to express the different ISGs, thus, could not identify those that were previously reported to restrict HIV replication. Several restriction factors like TRIM5a, APOBEC3G and BST-2/Tetherin, fit this group and were probably selected against in this specific assay.
In this report, the ability of human BST-2/Tetherin to modulate HCV production and release was investigated. BST-2 was initially recognized as a host factor that restricts the release of HIV-1 from infected cells. Since then it has emerged as an inhibitor of viral release of other enveloped viruses (Martin-Serrano and Neil, 2011) . However, its role in modulating HCV release has thus far not been thoroughly studied. HCV is believed to bud into the ER and is then released through the host TGN secretory pathway, where BST-2 is enriched (Andrew et al., 2011; Dube et al., 2009; Hauser et al., 2010; Masuyama et al., 2009) . Several reports showed that HCV replication occurs in detergent-insoluble sub-cellular domains or lipid rafts membrane web structures that serve as a scaffold for viral replication (Aizaki et al., 2004) . As BST-2 also partially resides in these micro-domains (Kupzig et al., 2003) , we investigated its presented as viral infectivity relative to wild-type HIV produced in Huh-7.5 cells and were representative of mean values of triplicate wells; error bars show the standard deviation of the means. To ensure equal levels of produced viruses, levels of p24-CA for HIV NL4.3 or HIV NL4.3 -delta Vpu were monitored by western blot analysis. Vpu expression was also validated by western blot analysis using anti Vpu polyclonal antibody, followed by anti-rabbit HRP conjugated secondary antibody. b-actin western blot verified equal protein levels that were loaded on the gel. role in restricting HCV production and release from Huh-7.5 cells. We demonstrated that in Huh-7.5 hepatocytes, only low basal expression levels of BST-2 were detected (Fig. 1) . Indeed, a recent report by Erickson et al. demonstrated relatively medium expression levels of BST-2 in liver tissue (Erikson et al., 2011) . We further showed that basal BST-2 expression levels in Huh-7.5 cells were not modulated following infection of cells with HCV (Fig. 2) . Treatment of Huh-7.5 cells with IFNa led to increased levels of BST-2 expression. Similarly, IFNa-induced expression of BST-2 was also not altered following HCV infection (Fig. 3) . This was not surprising since HCV could not replicate in IFNa À treated cells, confirming that HCV lacks mechanisms to modulate BST-2 expression that is IFNa induced. Moreover, expression of IFNa-induced BST-2 remained unchanged when cells were first infected with HCV and then treated with IFNa (Fig. 3) . In Huh-7.5 cells that stably expressed BST-2 and were further sorted for high BST-2 expression to generate Huh-7.5-BST-2, expression levels of BST-2 were also not modulated upon HCV infection. These results support the overall conclusion that HCV lacks mechanisms to counteract BST-2 function (Figs. 4 and 5) . Immunostaining analysis confirmed that BST-2 does not co-localize with HCV (Fig. 5E) .
Nevertheless, the study herein demonstrated that stably expressed BST-2 blocked the release of HCV particles from viral producing Huh-7.5 cells, following electroporation of viral RNA, as well as restricted HCV release from Huh-7.5 infected cells (Figs. 6 and 7) . Surprisingly, unlike the case of HIV where cellassociated viral production is not disrupted, in HCV, moderate inhibitory effects of BST-2 were also detected on virus production associated within cells (Fig. 7) . As HCV assembly takes place inside cells, BST-2 may partially disrupt this step. Further experiments should validate this hypothesis. Similar effects on intracellular levels of BST-2 were documented for filoviral VLP release (Jouvenet et al., 2009 ). The reasons for not measuring dramatic accumulation of cell-associated viral proteins are not clear, but it may be that VLPs that are targeted by BST-2 are degraded at a higher rate from their synthesis. Alternatively, it may simply be the case that only a fraction of the viral proteins that are synthesized are actually released as particles. Thus, the amount of viral protein that is observed in cell lysates would be determined by its intrinsic turnover rate rather than particle release versus retention (Jouvenet et al., 2009) .
Our results only partially agree with a recent published paper by Ye et al., who demonstrated that Tetherin/BST-2 has negligible restriction activity on HCV (Ye et al., in press) . Their work measured effects of BST-2 on viral RNA synthesis and not on overall viral protein particle release. Significantly, in their . HIV-Vpu moderately overcomes the restriction of BST-2 on HCV release from Huh-7.5-BST-2: Huh-7.5 (gray bar) and Huh-7.5-BST-2 (white bar) cells were electroporated with RLuc-HCV RNA. Huh-7.5-BST-2 were also co-electroporated with RLuc-HCV RNA and with pCDNA3.1-Vpu expression plasmid (10 mg; white bar). At 72 h post-electroporation cell supernatants were collected and used to infect new Huh-7.5 cells. 72 h postinfection cells were harvested and subjected to renilla-luciferase assay for viral release in Huh-7.5 cells. RLU were normalized to ensure equal protein levels that were subjected to Renilla-luciferase assay. Results are representative of the mean values of triplicate wells; error bars show the standard deviation of the means. Western blot analysis confirmed Vpu expression in Huh-7.5-BST-2 that were also transfected with HIV Vpu.
experimental design, BST-2 was transiently expressed and, as shown by their immuno-fluorescence analysis, only a small fraction of cells expressed BST-2. In such experimental settings, effects of BST-2 on HCV release could not be measured properly, as in cells that did not express BST-2, HCV release was not restricted. In the current study, BST-2 was stably expressed in Huh-7.5 cells, which were further sorted based on their high BST-2 expression, to obtain Huh-7.5-BST-2 stable cells. In these cells, we observed that BST-2 moderately inhibited HCV production and release (Figs. 6 and 7) . Despite the disagreements, both reports concluded that in vitro, BST-2 holds minor effects and even has negligible activity in inhibiting HCV release, while the virus could not counteract BST-2 activity. Current model for the antiviral activity of BST-2 implies that inhibition of viral release is non-specific. BST-2 dimerizes on the cell surface and facilitates physical tethering of viral particles on the surface of infected cells. Thus, enveloped viruses that bud through the plasma membrane have been placed under evolutionary pressure to antagonize BST-2 activity. The fact that viral replication of several viruses from different families code for BST-2 antagonists with distinct mode of action to counteract BST-2 activity, points to an important antiviral function for BST-2, which was conserved in evolution (Erikson et al., 2011) . For HCV, which does not bud via plasma membrane, viral measurements that were required to overcome BST-2 inhibition were not essential. Moreover, along its evolutionary development, HCV acquired alternative strategies to efficiently replicate in hepatocytes, mainly by disrupting the IFNa pathway and suppressing ISGs expression. This turned HCV to be less susceptible to anti-viral effects of BST-2, when compared to other viruses like HIV. In this study we confirmed that BST-2 is functional in Huh-7.5 cells, as it efficiently restricted the release of HIV-1 delta-Vpu from Huh-7.5-BST-2 cells as well as of HCV. Over expression of HIV Vpu rescued HIV delta-Vpu release from Huh-7.5-BST-2 (Fig. 8) . Additionally, HIV Vpu, moderately overcame BST-2 mediated inhibition of HCV release, and slightly down-regulated the surface expression of BST-2 (Fig. 9) . Overall, we suspect that, the in vitro moderate activity of BST-2 in down regulating HCV replication and release may imply that BST-2 inhibition of HCV replication and release is not of high relevance in vivo, and it is unlikely to be accountable as a major mechanism by which IFNa inhibits HCV replication in vivo. Nevertheless, as BST-2 is expressed in lipids rafts and ER membranes, where HCV replicates and buds, and its expression levels are moderately high in vivo, the biological significance of BST-2 on HCV replication and release should be further evaluated. BST-2 expression levels in locations where HCV replicates or assembled should be monitored (Lopez et al., 2012) . As IFNa still remains the backbone of HCV therapy and the antiviral functions and mechanisms of numerous ISGs are still incompletely understood, the biological significance of BST-2 needs further investigation in vivo as it may enhance our understanding of the late steps of HCV life cycle and may lead to presently unforeseen antiviral treatments.
Materials and methods

Cells and viruses
Huh-7.5 HCV permissive cells lines were a kind gift of Dr Charles Rice (Rockefeller University). Cells were cultured at 37 1C, 5% CO 2 in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) containing 10% fetal bovine serum (FBS) and 1 mM nonessential amino acids (NEAA -Gibco). HEK293T cells were grown in similar condition with no addition of NEAA. FL-J6/JFH-5.C19Rluc2AUbi (RLuc-HCV) is a monocistronic, full-length HCV genome derived from the infectious genotype 2a HCV genome J6/JFH1 as described previously . RLuc-HCV encodes the first 19 residues of the HCV Core protein fused to the N terminus of the RLuc Renilla luciferase gene. To allow removal of Rluc from the HCV polyprotein, a 17-residue fragment of the self-cleaving foot-and-mouth disease virus 2A protein (2A) and the ubiquitin monomer (Ubi) were fused to the C terminus of Rluc as described (Tscherne et al., 2006) .
In vitro transcription, electroporation and infection
RNA in vitro transcription was performed as previously described . Briefly, Xba-I linearized DNA template of the RLuc-HCV plasmid was transcribed by using T7 RiboMAX TM Express Large Scale RNA Production System (Promega) and the HCV-RNA was purified using the RNeasy Mini kit (QIAGEN) with on-column DNase treatment. Electroporation -Sub-confluent Huh-7.5 cells were trypsinized, harvested by centrifugation (500g for 5 min), washed twice, and resuspended in ice-cold phosphate-buffered saline (PBS; Biological Industries) at 1.5 Â 10 7 cells/ml. RLuc-HCV RNA (5 mg) was mixed with 0.4 ml of cells in a 0.4-cm gap corvette and immediately pulsed once with 270 V using a Gene-Pulser Xcell TM Electroporation System (BioRad). Electroporated cells were allowed to recover for 10 min at room temperature prior to the addition of complete medium and were then plated in a 150-mm diameter cell culture dish. After 96 h, electroporated cells were trypsinized and re-plated in complete medium. Virus stocks containing supernatant from re-plated cells were then harvested for 4 additional days of growth. Viral stocks were stored at À 80 1C until use.
Generation of Huh-7.5-BST-2 stable cell line
The human-BST-2 gene was amplified by PCR and was further sub-cloned into a lentiviral vector, which also expressed a puromycin selective marker that was translated via an IRES sequence. VSV-G pseudotyped lentiviral particles that expressed human BST-2 were generated by co-transfection of HEK293T cells with HIV packaging plasmids (Tat;Rev, vpu) and the BST-2 expression lentiviral vector. 48 h post-transfection, supernatant containing the CMV-BST-2-IRESpuromycin lentivirus was collected, filtered and used to infect Huh-7.5 cells. Transduced cells were selected for two weeks in complete media supplemented with 6 mg/ml puromycin. Expression of stable of BST-2 was validated by western blot and FACS analysis using anti BST-2 polyclonal antibody. Huh-7.5 cells that were expressing BST-2 were further sorted based on high expression of BST-2 to obtain Huh-7.5-BST-2 stable cells.
HCV concentration
Supernatant of Huh-7.5 cells electroporated with HCV RNA was collected at different time points and clarified by centrifugation at 3000 rpm for 10 min (4 1C). All batches containing the virus were mixed and Polyethylene glycol (PEG -MW 10000) solution (pH-7.2) was added at a ratio of 1:4 (PEG:Virus). The solution was incubated overnight at 4 1C and at the next day was centrifuged at 2300 rpm for 45 min (4 1C). The supernatant was removed and the pellet containing the virus was resuspended in 1/100 of the original volume. Finally the virus was aliquoted and stored at À 80 1C.
Luciferase renilla assay
To harvest samples for luciferase assays, cells were washed once with PBS and then were lysed with 100 ml of renilla lysis buffer (Renilla Luciferase Dual Assay System; Promega). Lysates were frozen at À 80 1C and were then thawed and vortexed. 50 ml of sample was mixed with luciferase assay substrate (Promega) and their luciferase activity was measured, using a Turner Designs illuminometer Model TD-20/20 (Promega). Relative Light Units (RLU) values were normalized to the protein amount in each sample by measuring protein concentration using the Thermo Scientific Pierce BCA Protein Assay Kit.
FACS
To assess BST-2 expression, cells were trypsinized, washed twice with PBS and were fixed with PFA 2% at room temperature. Cells were washed again and blocked for 1 h at room temperature with 4% FCS. For premeabilization of cells, blocking solution was supplemented with 0.05% Triton x100. Cells were then washed and stained with anti-human polyclonal BST-2 antibody (NIH #11721) for 30 min at 4 1C. Cells were then washed three times with cold PBS and were further incubated with Rhodamine Red-X-conjugated goat anti-rabbit (Jackson Immuno-Research Laboratories) for 30 min at 4 1C in darkness. The expression levels of BST-2 were analyzed by a flow cytometer FACSCalibur flow cytometer (Becton Dickinson, Mansfield, MA). For validating HCV replication, cells were also incubated with anti-NS5A monoclonal antibody, following by staining with anti-mouse-FITC conjugated antibody (Invitrogen). Expression of HIV Vpu was also analyzed by FACS, using anti Vpu polyclonal antibody.
Effects of HIV Vpu on the expression of BST-2 in Huh-7.5 cells
To analyze the ability of Vpu to down regulate BST-2 expression in Huh-7.5-BST-2, pCDNA3.1 Vpu was transfected into Huh-7.5-BST-2 cells using lipofectamine 2000. 48 h post-transfection, BST-2 expression levels were analyzed by FACS using rabbit BST-2 antibody and a secondary anti-rabbit Rhodamine Red-X. Vpu expression was detected with an anti Vpu polyclonal antibody, followed by staining of cells with a secondary rabbit FITC conjugated antibody (in the case of FACS analysis) or a secondary antibody that was HRP conjugated (for western blot analysis).
Release of HIV from Huh-7.5-BST-2 cells
To analyze the effects of BST-2 on the release of HIV and HIV-delta Vpu from Huh-7.5-BST-2, 15 mg of wild type HIV NL4.3 or HIV NL4.3 -delta Vpu proviruses DNA plasmids were transfected into Huh-7.5 or Huh-7.5-BST-2 using lipofectamine 2000. To analyze the effect of Vpu, 2 mg of pCDNA 3.1-Vpu was also co transfected (empty pCDNA 3.1 vector was transfected into cells that did not expressed Vpu). Virus particles were harvested 48 h post-transfection and were used to infect HeLa TZM-bl for b-Gal activity as readout of HIV particle release. Vpu was also cotransfected with the proviral DNA to analyze its ability to rescue HIV-delta Vpu release from Huh-7.5-BST-2 cells.
Immunofluorescence analysis
Cells were plated on sterile cover slips, which were coated with collagen and plated in a 6 well plate. 48 h later, the cells were gently washed with PBS and fixed with PFA 2% at room temperature. Cells were washed again and blocked for 1 h at room temperature with 4% FCS, supplemented or not with 0.05% Triton Â 100 for premeabilization. Cells were then washed and stained with a polyclonal anti-human BST-2 for 30 min at room temperature. After washing the cells with PBS, cells were incubated with Rhodamine Red-X conjugated-secondary antibody (Jackson Immuno-Research Lab) for 30 min in darkness at room temperature. Finally, cells were washed 3 times with PBS and then the cover slips were dried, mounted and let to dry for 24 h, before analyzed by confocal microscopy. For analysis of HCV infection, cells were permiabilized and also stained with a monoclonal NS5A antibody, followed by staining with anti mouse FITC conjugated antibody (Invitrogen). Cells were washed and mounted for fluorescence microscopy. Images were acquired by using Nikon inverted TI microscope (Nikon) with a X40 objective and a cooled 14bit CCD camera (Coolsnap HQ2, Photometrix, Tucson AZ), using NIS-elements software package (Nikon).
Western blotting analysis
For the analysis of BST-2 expression, cells were harvested and washed twice with cold PBS. The final cell pellet was re-suspended in ice cold RIPA buffer containing protease inhibitors, incubated for 30 min on ice and centrifuged at 13,000g for 30 min at 4 1C. The obtained supernatants were designated as the total cell lysates and their protein concentrations were determined by Bio-Rad protein assay using Dye Reagent (BioRad). Samples were subjected to SDS-PAGE under reduced conditions and were then transferred onto nitrocellulose membrane (Pall Corporation, Pensacola, FL, USA). Blocked membranes were probed with polyclonal antibody against the human BST-2 and with a secondary HRP-conjugated anti-rabbit antibody (Jackson Immuno-Research Lab). Western blot for Vpu were performed using an anti Vpu polyclonal antibody following by probing the membrane with a secondary anti-rabbit HRP conjugated antibody. CA-p24 expression was validated by western blot analysis with a goat a-p24-HRP conjugated (Serotec). b-actin was monitored with a monoclonal antibody (SIGMA). Finally, the immunoreactive proteins were visualized using enhanced chemiluminescence (ECL, Biological Industries).
Analysis of HCV production and viral release
For measuring HCV production, cells were electroporated with viral RNA and at different time points post-electroporation, cells were lysed and their luciferase activity was measured as described by the manufacture (Promega). For analysis of HCV particle release following transfection or infection, infectivity release assays were performed. Supernatant from viral producing cells or infected cells was collected at different time points, clarified and used for infection of new Huh-7.5 cells. Infected cells were further grown for additional 72 h and were then harvested for measuring their renilla-luciferase activity.
